Skip to main content
medical advertising in Thailand

Medical Advertising in Thailand: Why Clinic Owners Now Face Personal Claims

A Bangkok beauty clinic lost a consumer case this August, and the court ordered damages of only THB 20,000. That number is the least interesting part of the outcome. Instead, medical advertising in Thailand now sits inside two separate liability systems. Crucially, the second one reaches individuals rather than balance sheets. Regulators police a pre-approval regime under the Medical Facility Act. Patients, meanwhile, can sue directly under a procedural code built to favour them. For clinic groups, medical tourism operators and investors in Thai healthcare, the marketing function has quietly become a legal exposure.

Two Separate Rules Now Govern Medical Advertising in Thailand

Most operators treat clinic promotion as a regulatory question alone. However, that view is now incomplete. Two tracks run in parallel, and they behave very differently.

First, the administrative track. Section 38 of the Medical Facility Act B.E. 2541 (1998) requires prior approval for any advertisement concerning a medical facility. That wording arrived with the Medical Facility Act (No. 4) B.E. 2559 (2016). Subsequently, the Department of Health Service Support (DoHSS) issued the implementing notification. Its rules on procedures, conditions and fees took effect on 25 November 2019.

The second track is private. Here, a patient who relied on a misleading claim sues the clinic directly. That route runs under the Consumer Case Procedure Act B.E. 2551 (2008). Crucially, it does not depend on any regulatory finding. Indeed, a clinic can hold a valid approval and still lose a consumer case on the same material.

Key takeawayRegulatory approval shields you against enforcement, but not against patients. Because the two tracks run independently, clearing one does not clear the other.

What Actually Counts as an Advertisement

The Definition Reaches Far Beyond Paid Media

The DoHSS notification defines advertising expansively. It captures any act, by any means, that reaches the public. The message, sound or image simply has to serve the commercial benefit of a medical facility. Consequently, the perimeter runs far wider than a media buy.

In practice, therefore, the following all fall inside it:

  • Clinic websites, landing pages and booking funnels
  • Organic social posts on Facebook, Instagram, TikTok and LINE
  • Before-and-after imagery and patient testimonials
  • Influencer and key opinion leader content paid for by the clinic
  • Aggregator listings and medical tourism packages sold abroad
  • Physician credentials and specialty claims used in promotion

The Only Real Exemption Is Very Narrow

One carve-out exists. An advertisement limited to the registered name and address needs no approval. Otherwise, anything describing a treatment, a result, a technology or a practitioner falls straight back inside the requirement.

Penalties Regulators Apply to Medical Advertising in Thailand

The statutory penalties look modest on paper. However, the daily fine and the takedown power matter far more than the headline figures. Therefore, read the table below from the bottom up.

Conduct Provision Exposure
Advertising without DoHSS approval Section 38, paragraph one Fine of up to THB 20,000
Misleading, exaggerated or materially deceptive advertising Section 38, paragraph two Imprisonment of up to one year, a fine of up to THB 20,000, or both
Failure to comply with a takedown or correction order Section 39 Further fine of up to THB 10,000 for each day the breach continues

Note the criminal element in the second row. Imprisonment exposure attaches to a natural person, not to a company. Consequently, for an owner-operator physician, that distinction is not academic.

Why a Private Consumer Claim Outweighs the Fine

The August judgment involved a clinic advertising acne scar treatment. Specifically, the promotional material claimed specialist supervision and permanent results from stem cell technology. Ultimately, the court held the clinic liable for false representation. It then awarded compensation with interest.

Read as a damages award, the case looks trivial. As procedure, though, it looks very different. Specifically, the Consumer Case Procedure Act tilts the field in six ways:

  • No court fees. Consumers are generally exempt, so the cost barrier to suing largely disappears.
  • Oral filing. A claim may be lodged orally, because case officials help consumers frame it.
  • Shifted burden. Where facts sit specifically within the operator knowledge, the operator must prove them.
  • Court-led questioning. The judge examines witnesses, which reduces the advantage of a better-resourced defendant.
  • Punitive damages. Where actual damages stay under THB 50,000, the court may award up to five times that figure.
  • Emotional distress. Compensation covers anxiety and humiliation too, not only out-of-pocket loss.

Put together, these features make small claims cheap to bring. They also make them awkward to defend. Moreover, a clinic with thousands of patients faces a repeatable claim rather than a one-off.

Key takeawayThe commercial risk is volume, not quantum. Moreover, one adverse finding creates a template. Any patient who saw the same campaign can then copy it.

How Medical Advertising in Thailand Creates Personal Liability

The sharpest feature of the case is who paid. Notably, the court held the physician-owner jointly responsible alongside the company. He wore two hats: authorised director of the operating entity, and the clinician who delivered the treatment.

Those two roles collapse easily in Thai clinic structures. Consider a doctor who signs the filings, fronts the marketing and performs the procedure. The corporate form does not shield him. Under section 420 of the Civil and Commercial Code, he commits a tort in his own right. Company liability therefore sits beside that personal liability rather than absorbing it. Before any campaign can run, the device itself must clear Thailand medical device registration with the Thai FDA, and the claims advertised must match the approved dossier.

Three further consequences follow for the practitioner:

  • Meanwhile, Medical Council of Thailand disciplinary proceedings run as a third, independent track
  • Separately, directors of foreign-invested clinics may breach fiduciary duties owed to the company
  • Criminal exposure under section 38 attaches personally, with immigration consequences for foreign directors

Foreign investors should read this alongside the wider question of director duties and liabilities under Thai law. Standard indemnities, after all, rarely cover the marketing function.

Status note: the section 38 pre-approval requirement and the 2019 DoHSS notification are both in force. However, the August 2026 judgment described here is a first-instance decision of the Civil Court. It remains open to appeal. Furthermore, Thai courts do not apply binding precedent, so the reasoning is persuasive rather than determinative. Nothing here amounts to a rule change; rather, it shows how existing law is being applied.

A Practical Checklist for Medical Advertising in Thailand

Clinics rarely fail because of one bad advertisement. Rather, they fail because nobody owns the perimeter. Accordingly, the sequence below closes most of the gap.

  1. Map every channel. First, list each surface where the clinic name appears commercially. Include agency-run accounts and aggregator listings.
  2. Verify approval coverage. Next, match live creative against approved copy. Treat variations as new material rather than as minor edits.
  3. Ban absolute outcome language. Words such as permanent, guaranteed, cure and safest invite both regulatory and consumer challenge.
  4. Substantiate every technology claim. Terms like stem cell carry specific regulatory meaning. Consequently, unsupported use is hard to defend.
  5. Contract the agency inside the perimeter. Add approval warranties, indemnities and takedown obligations to the marketing agreement.
  6. Govern influencer content. Written briefs, prohibited claims and pre-publication sign-off should apply to every paid creator.
  7. Separate the roles where possible. Consider whether the treating clinician also needs to be the authorised director of the operating company.
  8. Check the insurance. Finally, note that professional indemnity and directors cover often exclude advertising liability and regulatory fines.

Investors buying into a clinic group should also treat advertising archives as a diligence item. After all, historic campaigns create live claims. Moreover, the limitation clock runs from patient awareness rather than from publication.

Frequently Asked Questions on Medical Advertising in Thailand

Does every clinic advertisement need DoHSS approval?
Almost every one does. The only meaningful exemption covers material limited to the registered name and address. However, as soon as a treatment, result, technology or practitioner appears, section 38 applies.
Do social media posts count as medical advertising in Thailand?
Yes. The DoHSS definition captures any act, by any means, that carries a commercial message to the public. Organic posts, stories, testimonials and influencer content therefore sit inside the same perimeter as paid media.
Can a patient sue even if the clinic holds a valid approval?
Yes. Approval addresses the regulatory track only. Therefore, a patient who relied on a misleading claim can still sue. The court will then assess that representation on its own merits.
Is the clinic owner personally exposed, or only the company?
Both can be exposed. Where the owner is also the authorised director and the treating clinician, courts may treat him as a joint tortfeasor. Similarly, criminal exposure under section 38 attaches to individuals rather than to the entity.
How should foreign-owned clinics handle marketing agencies?
Bring the agency inside the compliance perimeter by contract. Approval warranties, claim restrictions, indemnities and takedown obligations all belong in express terms. After all, regulators and patients will pursue the clinic rather than the agency.

What This Means Commercially

Thailand still attracts heavy capital into aesthetics, wellness and medical tourism. Growth there depends on aggressive patient acquisition. Aggressive acquisition, in turn, depends on claims. That tension is the risk.

The August judgment does not change the statute. Instead, it shows Thai courts looking past the corporate wrapper. They held the person who made the promise responsible. Consequently, clinics that treat marketing as a purely commercial function will keep generating unseen liabilities. Those that move advertising sign-off next to clinical governance will not.

Operators weighing entry or expansion should also review the licensing and structuring picture. Our guidance covers healthcare investment in Thailand and beauty clinic contracts. Advertising sits on top of those foundations. Weaknesses below the surface, meanwhile, tend to surface first in a consumer claim.

For primary sources, see the Department of Health Service Support. The Office of the Consumer Protection Board publishes complaint procedures.

This article provides general information as at 11 September 2026 and does not constitute legal advice. Regulatory positions and court practice change. Clinics and investors should obtain advice on their own facts before relying on anything set out above.

Review Your Clinic Advertising Before It Reaches a Courtroom

Lex Bangkok advises international clinic groups, medical tourism operators and healthcare investors in Thailand. Our work covers licensing, advertising compliance and director exposure. We audit live campaigns against section 38, rebuild agency and influencer contracts, and defend proceedings. Speak to our team about a structured advertising compliance review.

Schedule a Consultation